sirolimus has been researched along with Melena* in 2 studies
2 other study(ies) available for sirolimus and Melena
Article | Year |
---|---|
Sirolimus treatment of a PTEN hamartoma tumor syndrome presenting with melena.
PTEN hamartoma tumor syndrome (PHTS) is an umbrella term including Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome. One of the disorders in PHTS spectrum, CS is characterized by macrocephaly, mucocutaneous findings, gastrointestinal system (GIS) polyposis and an increased lifetime risk of GIS, breast, thyroid and other cancers.. In this study, we report an adolescent patient presenting with recurrent life-threatening upper GIS bleeding as a result of hamartomatous polyposis. Genetic studies revealed a known pathogenic nonsense mutation confirming the initial diagnosis of CS.. Additionally, we describe our therapeutic intervention to improve the patient`s clinical symptoms with sirolimus, which its use is infrequently addressed in the literature for pediatric age group harboring PTEN mutations. Topics: Adolescent; Child; Hamartoma Syndrome, Multiple; Humans; Melena; PTEN Phosphohydrolase; Sirolimus; Thyroid Gland | 2022 |
Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus.
Sirolimus is emerging as a popular immunosuppressive agent for patients undergoing solid organ and pancreatic cell transplantation. Here, we report the clinical courses of three patients receiving sirolimus who developed aggressive gastroduodenal ulcer disease. One patient died from massive gastrointestinal bleeding, and ulcers in the other two patients healed only after discontinuation of sirolimus. We propose that the mechanism underlying this severe ulcer diathesis, and poor ulcer healing, was linked to the well-known inhibitory effects of sirolimus on wound healing. We propose that sirolimus should be used carefully (or even withheld) in patients with known or previous ulcer disease, and further that it should be used prudently and/or in conjunction with aggressive prophylaxis therapy in those at risk for ulcer disease. Topics: Adult; Drug Monitoring; Duodenal Ulcer; Female; Follow-Up Studies; Hematemesis; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Melena; Middle Aged; Peptic Ulcer Hemorrhage; Sirolimus; Stomach Ulcer; Wound Healing | 2005 |